High volume Low volume HORRAD STAMPEDE Failure-free survival

Slides:

Advertisements

Similar presentations

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Advertisements

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

The SPRINT Research Group

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Lung squamous cell carcinoma

Intention-to-treat population

Volume 195, Issue 5, Pages (May 2016)

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Figure 1. (a) Dose distribution of dynamic conformal photon therapy

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Table 2. Progression-Free Survival

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 15, Issue 4, Pages (April 2014)

Patients who have received chemotherapy (n=60)

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Disease-specific survival

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial Marianna Christodoulou,

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

CYCLE 1A Supplemental Figure

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Volume 385, Issue 9962, Pages (January 2015)

Supplementary Figure 2 Shiota et al.

Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small.

Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating.

Volume 376, Issue 9757, Pages (December 2010)

Volume 67, Issue 1, Pages (January 2005)

Volume 392, Issue 10162, Pages (December 2018)

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Supplementary Figure 2A

Volume 373, Issue 9658, Pages (January 2009)

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group.

Volume 152, Issue 1, Pages (January 2019)

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease:

Volume 53, Issue 6, Pages (June 2008)

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Evaluating the Totality of Evidence

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Treatment of Stage III Non-small Cell Lung Cancer

SIMPSON’S PARADOX.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Uncovering the Right Sequence

Presentation transcript:

High volume Low volume HORRAD STAMPEDE Failure-free survival Progression-free survival HORRAD12 STAMPEDE11 Overall survival Trial name Outcome and 151/177 23/39 355/405 230/387 124/177 13/39 304/405 179/387 119/177 12/39 222/405 101/387 events/patients RT+ADT 165/181 22/35 364/416 284/385 129/181 16/35 300/416 188/385 124/181 15/35 217/416 120/385 ADT Favours .5 1 2 p=0.003 1.40 (1.12, 1.74) 1.10 (0.58, 2.09) 1.44 (1.14, 1.82) p=0.054 1.28 (1.00, 1.64) 1.96 (0.88, 4.38) 1.22 (0.94, 1.59) p=0.017 1.44 (1.07, 1.95) 1.98 (0.86, 4.53) 1.38 (1.00, 1.90) HR (95% CI) Interaction 100.00 11.60 88.40 9.63 90.37 13.21 86.79 Weight % Greater treatment effect with higher Volume of disease with lower Supplementary Figure 2: (Exploratory) Effect of adding prostate radiotherapy to ADT on overall survival, progression-free survival and failure-free survival by volume of disease